Sanuwave Health Inc (SNWV)

$SNWV Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.17 up 76.39% YoY • Reported revenue of $9.62M up 3.06% YoY • SANUWAVE forecasts Q2 2026 revenue of $11.1M to $11.6M, a 10-15% increase from Q2 2025, and reiterates full year 2026 revenue guidance of $51M.

$SNWV RSI: 39.58, MACD: -0.9083 Vol: 1.39, MA20: 17.93, MA50: 19.96 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

$SNWV yep they are hammering it OpalEye are friends with Morgan too This is not good at all

$SNWV https://www.investing.com/news/insider-trading-news/opaleye-management-sells-127m-in-sanuwave-health-stock-93CH-4651219

$SNWV Well they're still up to their old trick of publishing "Record Results and Financial Results" but let's see how much they actually get to keep after their previously recorded (and botched) filings cost them additional taxes, interest and penalties. And let's see if they even bother to update investors March 27th. https://www.publicnow.com/view/DEE2A4E7783985D787D75AA2065C87B7C1980DDF

$SNWV Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.71 up 128.51% YoY • Reported revenue of $13.09M up 26.81% YoY • Sanuwave forecasts Q1 2026 revenue of $9.6M, an increase of 3-10% from Q1 2025. Full year 2026 revenue guidance is $51M, representing 16-25% growth versus 2025.

$SNWV said old financials should not be relied on anymore...

$SNWV Time for a new CEO and audit committee! Sanuwave Health, Inc. determined that several previously issued quarterly and annual financial statements can no longer be relied upon due to unrecorded state sales and use tax obligations. The company plans to restate its 2024 annual results and all affected 2024–2025 interim periods in its 2025 Form 10-K. Based on its ongoing review, Sanuwave expects to record an aggregate increase in reported liabilities of between $4.9 million and $5.2 million as of December 31, 2025. It also expects additional expenses, including taxes, interest and penalties, of $1.6 million to $1.8 million for 2024 and $1.7 million to $1.9 million for 2025. Management is evaluating the impact on internal control over financial reporting and may identify additional material weaknesses, with conclusions to be disclosed in the 2025 Form 10-K, which it expects to file on time.

$SNWV More importantly......Morgan and his fund SOLD BEFORE BAD GUIDANCE and BEFORE THIS AUDIT PROBLEM Hmmmm

$SNWV not good at all

$SNWV What does this mean? https://www.tradingview.com/news/reuters.com,2026:newsml_FWN4011ED:0-sanuwave-health-audit-committee-concludes-prior-financial-statements-for-multiple-periods-should-not-be-relied-upon/

$SNWV Current Stock Price: $24.31

$SNWV RSI: 25.24, MACD: -1.2139 Vol: 1.04, MA20: 26.11, MA50: 28.69 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

$SNWV added here… again. It’s a long term play but they are positioned well.

Sudden, temporary vision loss is easy to dismiss, especially when it resolves quickly. But as a new article from NovaVision, the vision rehabilitation division of Vycor Medical, explains, it can be one of the earliest warning signs of an approaching stroke. A transient ischemic attack, or TIA, often produces brief vision changes, including dimming or complete loss of sight in one eye, that can signal something more serious ahead. Vycor Medical, Inc. (OTCQB: $VYCO) is a B2i Digital Featured Company. See the company’s complete profile at https://b2idigital.com/vycor-medical. The article explores how sudden vision changes can serve as early stroke warnings, what types of vision loss commonly follow a stroke, and what rehabilitation options are available. As the article notes: “If you experience sudden vision loss, whether in one eye or across part of your visual field, along with any other stroke-associated symptoms, seek medical attention immediately. Acting fast is the single most important thing you can do to reduce the impact of a stroke.” Read the full article here: https://novavision.com/vision-loss-as-a-warning-sign-of-stroke/ Vycor operates two divisions: Vycor Medical (ViewSite Brain Access System™ for neurosurgery) and NovaVision (vision rehabilitation therapies for stroke and brain injury patients). The company is led by CEO Peter Zachariou, President David Cantor, and CFO Adrian Liddell, each bringing extensive experience in medical technology, business development, and finance. More information is available at https://vycormedical.com/investors/. For investor inquiries, please contact [email protected]. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased and currently owns shares of unrestricted VYCO stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of VYCO or any security, nor is it intended to offer any opinion on VYCO as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $CTSO, $SNWV, $IHI

$SNWV Current Stock Price: $26.75

Vision changes after a stroke can develop gradually and go unnoticed during recovery. Vycor’s NovaVision division provides a free online visual field screening tool that help stroke survivors check for potential changes and support informed conversations with their healthcare providers. Vycor Medical, Inc. (OTCQB: $VYCO) is a B2i Digital Featured Company. See the company’s complete profile at https://b2idigital.com/vycor-medical. In a new blog post, Vycor discusses five practical reasons online screening can be valuable, including accessibility and convenience, as well as early awareness of issues. As the article notes: “Screening results give you concrete information to discuss with your healthcare team. Rather than describing vague concerns about your vision, you can share screening results that show specific patterns.” Read the entire article here: https://novavision.com/five-reasons-to-consider-online-visual-field-screening/ Vycor operates two divisions: Vycor Medical (ViewSite Brain Access System™ for neurosurgery) and NovaVision (vision rehabilitation therapies for stroke and brain injury patients). The company is led by CEO Peter Zachariou, President David Cantor, and CFO Adrian Liddell, each bringing extensive experience in medical technology, business development, and finance. More information is available at https://vycormedical.com/investors/. For investor inquiries, please contact [email protected]. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased and currently owns shares of unrestricted VYCO stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of VYCO or any security, nor is it intended to offer any opinion on VYCO as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $CTSO, $SNWV, $IHI

$SNWV (+4.6% pre) Sanuwave Health Q4 Preliminary Revenue Climbs https://ooc.bz/l/89180

$SNWV Still holding but it's been a huge disappointment. Management won't reward shareholders at all. Sell the company.

$SNWV Morgan Frank Shadiness….